Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
05. März 2025 16:05 ET
|
Zymeworks Inc.
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting...
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
26. Februar 2025 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
25. Februar 2025 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
18. Februar 2025 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
13. Februar 2025 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
30. Januar 2025 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
08. Januar 2025 16:05 ET
|
Zymeworks Inc.
Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for...
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
12. Dezember 2024 08:30 ET
|
Zymeworks Inc.
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T cell...
Zymeworks Announces Participation in Upcoming Investor Conferences
21. November 2024 06:05 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
21. November 2024 06:00 ET
|
Zymeworks Inc.
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response...